Sonja Visscher

474 total citations
7 papers, 267 citations indexed

About

Sonja Visscher is a scholar working on Genetics, Oncology and Immunology. According to data from OpenAlex, Sonja Visscher has authored 7 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 3 papers in Oncology and 3 papers in Immunology. Recurrent topics in Sonja Visscher's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers), Mast cells and histamine (2 papers) and Hemophilia Treatment and Research (2 papers). Sonja Visscher is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers), Mast cells and histamine (2 papers) and Hemophilia Treatment and Research (2 papers). Sonja Visscher collaborates with scholars based in United States, Netherlands and Italy. Sonja Visscher's co-authors include Anurag Relan, Marco Cicardi, Jan H. Nuijens, Leonard Kaufman, Bruce L. Zuraw, Gerald M. Haase, C. Erik Hack, Robyn J. Levy, Avner Reshef and Dumitru Moldovan and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology and Annals of Oncology.

In The Last Decade

Sonja Visscher

6 papers receiving 258 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sonja Visscher United States	5	250	100	95	92	74	7	267
György Temesszentandrási Hungary	8	325 1.3×	132 1.3×	103 1.1×	91 1.0×	113 1.5×	11	375
Kinga Viktória Kőhalmi Hungary	10	243 1.0×	88 0.9×	64 0.7×	57 0.6×	85 1.1×	28	277
Daniel Soteres United States	9	168 0.7×	81 0.8×	48 0.5×	54 0.6×	51 0.7×	37	270
George Harmat Hungary	6	267 1.1×	104 1.0×	111 1.2×	105 1.1×	79 1.1×	8	290
Henrike Feuersenger United States	10	198 0.8×	72 0.7×	59 0.6×	53 0.6×	62 0.8×	30	233
Vesna Grivcheva‐Panovska North Macedonia	8	402 1.6×	168 1.7×	127 1.3×	116 1.3×	136 1.8×	16	427
Anna Valerieva Bulgaria	8	138 0.6×	45 0.5×	44 0.5×	42 0.5×	38 0.5×	25	178
I. Martinez‐Saguer Germany	8	305 1.2×	110 1.1×	113 1.2×	102 1.1×	130 1.8×	18	352
Ryan Iarrobino United States	6	147 0.6×	54 0.5×	32 0.3×	31 0.3×	35 0.5×	9	181
Beáta Visy Hungary	10	563 2.3×	235 2.4×	214 2.3×	209 2.3×	175 2.4×	22	604

Countries citing papers authored by Sonja Visscher

Since Specialization

Citations

This map shows the geographic impact of Sonja Visscher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonja Visscher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonja Visscher more than expected).

Fields of papers citing papers by Sonja Visscher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonja Visscher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonja Visscher. The network helps show where Sonja Visscher may publish in the future.

Co-authorship network of co-authors of Sonja Visscher

This figure shows the co-authorship network connecting the top 25 collaborators of Sonja Visscher. A scholar is included among the top collaborators of Sonja Visscher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonja Visscher. Sonja Visscher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Harrington, Kevin J., Erminia Massarelli, Sonja Visscher, et al.. (2024). Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).. Journal of Clinical Oncology. 42(16_suppl). 6003–6003. 9 indexed citations

Kong, Anthony, Begoña Aguilera, Sonja Visscher, et al.. (2024). 878P Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy. Annals of Oncology. 35. S627–S628.

Kong, Anthony, Begoña Aguilera, Douglas R. Adkins, et al.. (2023). Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.. Journal of Clinical Oncology. 41(16_suppl). 6028–6028. 4 indexed citations

Reshef, Avner, et al.. (2012). Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy. 68(1). 118–124. 34 indexed citations

Moldovan, Dumitru, Avner Reshef, Shmuel Kivity, et al.. (2012). Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study. Clinical & Experimental Allergy. 42(6). 929–935. 41 indexed citations

Zuraw, Bruce L., Marco Cicardi, Robyn J. Levy, et al.. (2010). Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology. 126(4). 821–827.e14. 174 indexed citations

Nuijens, Jan H., René Verdonk, Bruno Giannetti, et al.. (2008). Clinical Studies of Recombinant Human C1 Inhibitor (rhC1INH) in Patients with Acute Attacks of Hereditary Angioedema. Journal of Allergy and Clinical Immunology. 121(3). 797–797. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact